drugset / Trial / NCT00073892
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
Phase 1/2
Completed
44 enrolled
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.
Timeline
- Start
- 2004-01
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | muparfostat | Other / unclassified | 250 mg | Subcutaneous |